HomeFilePharmacology

Pharmacology

View Category

Acute coronary syndromes

Optimal Intervention Timing for NSTEMI with No Antiaggregant Pre-Treatment

Patients undergoing non-ST elevation MI (NSTEMI) who are not pre-treated with P2Y12 receptor inhibitors will benefit from...
solaci -
Learn More
Coronary disease

Estimating the Risk of Infection for Healthcare Personnel

Roughly one out of every 100 healthcare workers at hospitals receiving COVID-19 patients become infected. Statistics are not...
solaci -
Learn More
Other

SPARCL: Highly Effective Prevention of New Events with Atorvastatin after a Stroke

In patients with recent stroke or transient ischemic attack, the total number of vascular events prevented by...
solaci -
Learn More
Antiplatelet

Antiaggregation vs. Anticoagulation after Peripheral PCI

The truth is this question has no clear answer and what with do with peripheral stenting is...
solaci -
Learn More
Antiplatelet

Webinar SOLACI – 29/05 – Approach to Antiplatelet Therapy in Acute Coronary Syndrome

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be...
solaci -
Learn More
Pharmacology

Cerebrovascular Events After TAVR May Be Especially Serious

Stroke events do not seem to be related to valve thrombosis or structural degeneration, but to a...
solaci -
Learn More
Coronary disease

ECS Guidelines for COVID-19 Management

One of the first statements in this document points out these are not “regular guidelines” developed after...
solaci -
Learn More
Acute coronary syndromes

Are Non-Culprit Lesions Really Innocent?

In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy...
solaci -
Learn More